James R.  Gruber net worth and biography

James Gruber Biography and Net Worth

James brings more than 20 years of financial and accounting experience in the life sciences industry, including pharmaceuticals, medical devices, and hospital products.

Vice President, US Controller at Horizon Therapeutics, a branded pharmaceutical company where he was responsible for several areas of accounting, finance, and shared services, along with Sarbanes-Oxley compliance and the integration of several acquisitions of both public and private companies

Various finance and accounting roles across multiple divisions of Abbott Laboratories over 14 years within both domestic and international business units of Core Diagnostics, Pharmaceuticals (AbbVie), and Hospital Products (Hospira/Pfizer)

BA, Northwestern University, Kellogg School of Management

BS, Accounting, Indiana University

What is James R. Gruber's net worth?

The estimated net worth of James R. Gruber is at least $4.58 million as of August 19th, 2025. Mr. Gruber owns 205,299 shares of Eton Pharmaceuticals stock worth more than $4,582,274 as of March 23rd. This net worth approximation does not reflect any other assets that Mr. Gruber may own. Additionally, Mr. Gruber receives a salary of $554,440.00 as CFO at Eton Pharmaceuticals. Learn More about James R. Gruber's net worth.

How old is James R. Gruber?

Mr. Gruber is currently 52 years old. Learn More on James R. Gruber's age.

What is James R. Gruber's salary?

As the CFO of Eton Pharmaceuticals, Inc., Mr. Gruber earns $554,440.00 per year. The highest earning executive at Eton Pharmaceuticals is Mr. Sean E. Brynjelsen, President, CEO & Director, who commands a salary of $939,420.00 per year. Learn More on James R. Gruber's salary.

How do I contact James R. Gruber?

The corporate mailing address for Mr. Gruber and other Eton Pharmaceuticals executives is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. Eton Pharmaceuticals can also be reached via phone at (847) 787-7361 and via email at [email protected]. Learn More on James R. Gruber's contact information.

Has James R. Gruber been buying or selling shares of Eton Pharmaceuticals?

James R. Gruber has not been actively trading shares of Eton Pharmaceuticals during the last ninety days. Most recently, James R. Gruber sold 2,631 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $16.02, for a transaction totalling $42,148.62. Following the completion of the sale, the chief financial officer now directly owns 204,753 shares of the company's stock, valued at $3,280,143.06. Learn More on James R. Gruber's trading history.

Who are Eton Pharmaceuticals' active insiders?

Eton Pharmaceuticals' insider roster includes Sean Brynjelsen (CEO), James Gruber (CFO), and David Krempa (Chief Business Officer). Learn More on Eton Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Eton Pharmaceuticals?

In the last year, insiders at the sold shares 5 times. They sold a total of 75,713 shares worth more than $1,178,031.37. The most recent insider tranaction occured on August, 20th when CFO James R Gruber sold 2,631 shares worth more than $42,148.62. Insiders at Eton Pharmaceuticals own 14.9% of the company. Learn More about insider trades at Eton Pharmaceuticals.

Information on this page was last updated on 8/20/2025.

James R. Gruber Insider Trading History at Eton Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2025Sell2,631$16.02$42,148.62204,753View SEC Filing Icon  
8/19/2025Sell39,082$16.16$631,565.12205,299View SEC Filing Icon  
See Full Table

James R. Gruber Buying and Selling Activity at Eton Pharmaceuticals

This chart shows James R Gruber's buying and selling at Eton Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eton Pharmaceuticals Company Overview

Eton Pharmaceuticals logo
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Today's Range

Now: $22.87
Low: $22.04
High: $22.04

50 Day Range

MA: $16.72
Low: $14.35
High: $22.32

2 Week Range

Now: $22.87
Low: $11.09
High: $23.00

Volume

626 shs

Average Volume

284,353 shs

Market Capitalization

$623.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19